ImExHS Limited (ASX: IME) - ETF Exposure
- Current share price for IME : $0.355
MEXHS Limited (IME) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a provider of medical imaging software and radiology services in 18 countries including Colombia, the US and Australia. IMEXHS develops software as a service (SaaS) imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS).
IME General Information +
| ASX Code | IME |
| Website | N/A |
| Industry/Sector | Health Care Technology |
| Market Cap ($M) | 19 |
| IME Share Price | $0.355 |
| Day High | $0.355 |
| Day Low | $0.355 |
| Last Close | $0.355 |
| IME Share Price Movement | - ( No change ) |
Prices as at 16:40, 4 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
ImExHS Limited (IME) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from ImExHS Limited (IME) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
ImExHS Limited (IME) price-sensitive announcements
IME - Quarterly Activities/Appendix 4C Cash Flow Report
In the quarterly report for Q2 FY26, ImExHS Limited reported a net cash inflow of $0.1 mil
ImExHS Limited (IME)
31 Jul 2026 | 10:59 AM
31 Jul 2026 | 10:59 AM
IME - IMEXHS Wins Aquila Public Tender in Mexico
IMEXHS Limited announced winning a public tender for the deployment of its Aquila+ platfor
ImExHS Limited (IME)
25 May 2026 | 10:36 AM
25 May 2026 | 10:36 AM
IME - AGM - Chairman and CEO Addresses and Presentation
The document provides a detailed overview of ImExHS Limited's financial performance and st
ImExHS Limited (IME)
20 May 2026 | 9:20 AM
20 May 2026 | 9:20 AM
IME - FY26 Q1 Quarterly Activities Report and Appendix 4C
IMEXHS Limited reported strong performance in Q1 FY26, with revenues increasing by 13% fro
ImExHS Limited (IME)
30 Apr 2026 | 9:45 AM
30 Apr 2026 | 9:45 AM
ImExHS Limited (IME) Recent ASX Announcements
IME Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$1.13 | -$2.20 | -62.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$2.63 | -$5.80 | -16.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$2.92 | -$7.00 | -18.30% | 0.00 | 0.00 | 0.00% | 0.0% |
IME Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| 4DMedical Limited (4DX) | $2,064M | 1.4982 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| ImExHS Limited (IME) | $19M | -0.6216 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Pro Medicus Limited (PME) | $18,042M | 1.3034 | -0.2811 | 0.2395 | 68.0994 | 94.7288 | 76.4227 | 0.40% | 0.54% | 0.66% |
IME Directors
| Name | Position | Start Date |
|---|---|---|
| Dr German Arango | Chief Executive Officer, Managing Director | 28 Aug 2018 |
| Mr Douglas (Doug) Ronald Flynn | Non-Executive Chairman, Non-Executive Director | 12 Mar 2020 |
| Mr Damian Eric Banks | Non-Executive Director | 22 May 2020 |
| Mr Carlos Jaime Palacio | Non-Executive Director | 28 Aug 2018 |
| Dr Douglas Lingard | Non-Executive Director | 10 Dec 2018 |
ImExHS Limited (IME) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 9 Jun 2026 | BANKS, Damian | Sell | Direct Shares | 60,988 | $0.350 | $21,345.800 |
| 9 Jun 2026 | BANKS, Damian | Buy | Indirect Shares | 60,988 | $0.350 | $21,345.800 |
| 1 Jun 2026 | PALACIO, Carlos | Issued | Direct Shares | 60,988 | $0.410 | $25,000.000 |
See all changes in directors' interest & trades for ImExHS Limited (IME) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IME Management
| Name | Position |
|---|---|
| Fabio Carrillo | Chief Financial Officer |
| Jorge Marin | Chief Medical Officer & Co-Founder |
| Orlando Joven | Chief Operations Officer |
| Kamille Dietrich | Company Secretary |
| Sandra Nino | Medical Director |
| Elizabeth Mendez | Operations Manager and Contract Audit |
| Juan David Fajardo | VP Of Global Sales |
IME Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in ImExHS Limited (IME). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 9,645,191 (17.84%) | Sandhurst Trustees Ltd (Jmfg Consol A/C) |
| 3,407,708 (6.30%) | Digital Imaging Solutions SAS |
| 3,016,085 (5.58%) | Milla Paula Inari Palacio |
| 2,959,044 (5.47%) | Dixson Trust Pty Ltd |
| 2,909,091 (5.38%) | Barrijag Pty Ltd |
IME Calendar of Events
| Date | Event |
|---|---|
| 01 September 2027 | Report (Interim) |
| 27 August 2027 | Report (Interim) |
| 26 February 2027 | Report (Annual) |
| 26 February 2027 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
